Sun Pharma
 |
|
| Public | |
| Traded as | : : SUNPHARMA |
| Industry | Pharmaceuticals |
| Founded | 1983 |
| Founder | Dilip Shanghvi |
| Headquarters | Mumbai, Maharashtra, India |
|
Key people
|
Dilip Shanghvi (Managing Director) |
| Products | Pharmaceuticals, generic drugs |
| Revenue |
 ₹31,578 crore (US$4.9 billion) (Mar 2017) |
|
₹7,836 crore (US$1.2 billion) (Mar 2017) |
|
| Total assets |
₹54,219 crore (US$8.4 billion) (Mar 2016) |
|
Number of employees
|
52,700 (March 2016) |
| Website | www |
Sun Pharmaceutical Industries Limited (: SUNPHARMA, : ) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. The company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anticancers, steroids, peptides, sex hormones, and controlled substances.
Sun Pharmaceuticals was established by Mr. Dilip Shanghvi in 1983 in Vapi with five products to treat psychiatry ailments. Cardiology products were introduced in 1987 followed by gastroenterology products in 1989. Today it is the largest chronic prescription company in India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology, gastroenterology and nephrology.
The 2014 acquisition of Ranbaxy has made the company the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest specialty generic company globally.
Over 72% of Sun Pharma sales are from markets outside India, primarily in the US. The US is the single largest market, accounting for about 50% turnover; in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 26 locations, including plants in the US, Canada, Brazil, Mexico and Israel. In the US, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA).
...
Wikipedia